The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.
Raz MutaiIryna KuchukAlexandra GoldshteinRinat YerushalmiOfer RotemAdi Maisel LotanTali Bdolah-AbramAlberto GabizonHadar GoldvaserPublished in: Breast cancer research and treatment (2024)
Compared to wild-type, gBRCA carriers with locally advanced TNBC treated with neoadjuvant chemotherapy containing carboplatin had a higher pCR rate and better outcomes. These results strengthen the contention that gBRCA status should be considered when tailoring treatment decisions in women with locally advanced TNBC.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- phase ii study
- rectal cancer
- squamous cell carcinoma
- wild type
- radiation therapy
- sentinel lymph node
- lymph node
- copy number
- dna repair
- type diabetes
- clinical trial
- newly diagnosed
- metabolic syndrome
- randomized controlled trial
- gene expression
- weight loss
- combination therapy
- oxidative stress
- replacement therapy